|
Date
|
Agency
|
|
|
|
Marketwire
|
Entest BioMedical Successfully Completes First ImenVax(TM) Cancer Vaccine Implantation in Canine Oncology Patient
|
|
|
Marketwire
|
Entest BioMedical Signs LOI to Acquire a Veterinary Hospital Group With Three Locations in Southern California
|
|
|
Marketwire
|
Entest BioMedical Enters Escrow on Potential Acquisition of Veterinary Hospital Located in Southern California
|
|
|
Marketwire
|
Entest Biomedical inc. Enters Collaboration With RenovoCyte LLC and Medistem Inc. in Developing Stem Cell Therapy for Treating Canine Hip Dysplasia
|
|
|
Marketwire
|
Entest BioMedical's Chairman Provides Update on Veterinary Clinic Acquisitions, Business Expansion and ImenVax(TM) SafetyStudy
|
|
|
Marketwire
|
Entest BioMedical Announces the Completion of the McDonald Animal Hospital Acquisition / Entest Sees Immediate Revenue / Company Has Already Identified Several Other Candidates Pursuant to Its Business Model
|
|
|
Marketwire
|
Entest BioMedical Executes Definitive Purchase Agreement to Acquire McDonald Animal Hospital/ Entest's First Veterinary Clinic Acquisition Has Historical Revenues of $700,000 per Year/ Anticipated Strong Growth Potential With an Established Presence...
|
|
|
Marketwire
|
Entest BioMedical Provides Overview of Immuno-Therapeutic Canine Cancer Vaccine Safety Study / Study to Pave Way for Veterinary Use of Cancer Vaccine / Company Expecting Efficacy in Treating Canine Oral Melanoma / Anticipates Cancer Therapy Model Expansion
|
|
|
Marketwire
|
Entest BioMedical Chairman Discusses Anticipated Short Range and Mid-Range Milestones / Milestones to Include: Veterinary Clinic Acquisitions, Near Term Revenue, and ImenVax(TM) Safety Study
|
|
|
Marketwire
|
Entest BioMedical Announces Approval of Its Protocols for ImenVax(TM) Safety Study by CRO's Internal Animal Care and Use Committee / Company Has Begun Patient Profile Review in Preparation For Enrollments in ImenVax(TM) Safety Study
|
|
|
Marketwire
|
Entest BioMedical Announces the Addition of Well Respected Veterinarian to Its Scientific Advisory Board (SAB) in Anticipation of Near Term ImenVax(TM) Safety Study for Dogs
|
|
|
Marketwire
|
Entest BioMedical Anticipates First Veterinary Clinic Acquisition and Near Term Commencement of ImenVax(TM) Safety Study
|
|
|
Globe Newswire
|
Bio-Matrix Scientific Group Chairman Sees Future of Stem Cell Therapies Focused on Stem Cell Repositories
|
|
|
Globe Newswire
|
Entest Blogcast Today Covering Strategic Rollout for ImenVax
|
|
|
Globe Newswire
|
Blogcast on Strategic Rollout of ImenVax Immunotherapeutic Cancer Vaccine for Dogs
|
|
|
Globe Newswire
|
Entest BioMedical has Identified Several Veterinary Clinics as Possible Acquisition Candidates to Serve as Distribution Channel for Veterinary Therapeutic Treatments
|
|
|
Globe Newswire
|
Entest BioMedical Finalizing Protocols for ImenVax(TM) Safety Study
|
|
|
Globe Newswire
|
Entest BioMedical Retains Crescendo Communications as Investor Relations and Corporate Communications Advisor
|
|
|
Marketwire
|
Entest BioMedical Updates Status of Proposed Medistem Transaction, Discusses Potential Revenue Streams
|
|
|
Marketwire
|
Entest BioMedical CEO David Koos and Medistem CEO Thomas Ichim to Discuss Recent Announcement of Potential Business Combination
|
|
|
|
Entest BioMedical Announces Intent to Acquire Medistem
|
|
|
Marketwire
|
Entest BioMedical, Inc. Announces the Addition of New Chief Financial Officer to Management Team
|
|
|
|
Entest BioMedical CEO to Interview Noted Stem Cell Transplant Physician Dr. Ewa Carrier on Advances in Stem Cell Therapy
|
|
|
|
Entest BioMedical CEO & Lead Inventor Clarify Significance of Chemokine Technology in Potential Efficacy of COPD Stem Cell
/ Photoceutical Therapy
|
|
|
Marketwire
|
Entest BioMedical Files Patent Application on Chemokine Technology to Increase Efficacy of Tissue-Specific Stem Cell Homing
in COPD Treatment
|
|
|
|
Entest BioMedical Announces It Is Developing a Bioinformatics Model for COPD
|
|
|
Marketwire
|
Entest BioMedical, Inc. Chairman & CEO Addressed Shareholders on Its New Company Blog Site Regarding COPD and Immunotherapeutic
Cancer Vaccine
|
|
|
Marketwire
|
Entest BioMedical CEO to Address Shareholders on Entestbioblog.com/live
|
|
|
|
Entest BioMedical Strengthens Its Research Capabilities by Adding Clinical Trials Expert Dr. Vladimir Bogin to Its Scientific
Advisory Board
|
|
|
Marketwire
|
Entest BioMedical Announces Creation of Proprietary Adult Stem Cell Lines
|
|
|
Marketwire
|
Entest BioMedical Publishes Journal Article on Laser Activation of Stem Cell for Treatment of Chronic Obstructive Pulmonary
Disease (COPD)
|
|
|
Marketwire
|
Entest Biomedical Applying for NIH Grant for Studying Chemotherapy Resistance in Cancer Stems Cells
|
|
|
Marketwire
|
Bio-Matrix Scientific Group's Majority Owned Subsidiary Entest BioMedical Initiates Studies to Support Stem Cell / Laser Regenerative
Therapy for COPD
|
|
|
Marketwire
|
Bio-Matrix Scientific Group, Inc.'s Majority Owned Subsidiary Entest BioMedical, Inc. to Be Featured on Stem Cell Pioneers
"Ask the Doctor" Forum Discussing the Company's Progress on Its COPD Stem Cell / Laser Therapy
|
|
|
Marketwire
|
Entest BioMedical Projecting Near Term Start Up of Study on Stem Cell and Laser Treatment for COPD at Bio-Matrix Scientific
Group's Stem Cell Research Facility
|
|
|
Marketwire
|
Entest BioMedical Files Grant Application With the National Heart, Lung and Blood Institute for Development of the Company's
ENT-576 Laser Device for Treatment of COPD
|
|
|
Marketwire
|
Entest BioMedical Inc. (OTCBB: ENTB) Obtains Specimen to Be Used in Immunotherapeutic Cancer Vaccine Research
|
|
|
|
Entest BioMedical, Inc. Sees Substantial Opportunities in Treatment of Chronic Obstructive Pulmonary Disease
|
